

MC

Attorney's Docket No.: 07039-170002

BOX SEQ  
0300  
#12

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Jorg J. Goronzy et al.                      Art Unit : Unknown  
Serial No. : 09/723,000                                      Examiner : Unknown  
Filed : November 27, 2000  
Title : METHODS AND MATERIALS FOR EVALUATING RHEUMATOID  
ARTHRITIS

**BOX SEQUENCE**

Commissioner for Patents  
Washington, D.C. 20231

TRANSMITTAL LETTER

The following documents relating to this application are enclosed.

1. Response to Notice to Comply with Requirements for Patent Applications  
Containing Nucleotide and/or Amino Acid Sequences (5 pages);
2. Copy of Notice to Comply with Requirements (1 page);
3. Statement Under 37 CFR §§1.821(f) and (g) (1 page);
4. Verified Statement Under 37 CFR §1.821(f);
5. Paper copy of Sequence Listing (5 pages);
6. Computer-readable copy of Sequence Listing (1 disk); and
7. Postcard.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: March 22 2001

J. Patrick Finn III  
J. Patrick Finn III, Ph.D.  
Reg. No. 44,109

Fish & Richardson P.C., P.A.  
60 South Sixth Street  
Suite 3300  
Minneapolis, MN 55402  
Telephone: (612) 335-5070  
Facsimile: (612) 288-9696

60036206.doc

**CERTIFICATE OF MAILING BY FIRST CLASS MAIL**

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

March 22, 2001

Date of Deposit

Signature

Jill Huso

Typed or Printed Name of Person Signing Certificate

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Jorg J. Goronzy et al.                      Art Unit :  
Serial No. : 09/723,000                                      Examiner :  
Filed : November 27, 2000  
Title : METHODS AND MATERIALS FOR EVALUATING RHEUMATOID  
ARTHRITIS

Box Sequence  
Commissioner for Patents  
Washington, D.C. 20231

VERIFIED STATEMENT UNDER 37 CFR §1.821(f)

I, Jennifer H. Payne, declare that I personally prepared the paper and the computer-readable copy of the Sequence Listing filed herewith for the above-identified application and that the content of both is the same.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of The United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date:

February 23, 2001

  
Jennifer H. Payne


Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110-2804  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906

20191725.doc


CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

March 22, 2001  
Date of Deposit

  
Signature

Jill Huso  
Typed or Printed Name of Person Signing Certificate



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/723,000	11/27/2000	Jorg J. Goronzy	07039-170002

Mark S Ellinger PhD  
Fish & Richardson PC PA  
60 South Sixth Street  
Suite 3300  
Minneapolis, MN 55402

**FORMALITIES LETTER**

\*OC000000005692692\*

Date Mailed: 01/22/2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):
  - This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
  - A copy of the "Sequence Listing" in computer readable form has not been submitted as required under 37 CFR 1.821(e).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-1123
- For CRF Submission Help, call (703) 308-4212
- PatentIn Software Program Support
- - For Technical Assistance, call (703) 287-0200
- - To Purchase PatentIn Software, call (703) 306-2600

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center  
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE